<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976960</url>
  </required_header>
  <id_info>
    <org_study_id>BCB2014/01</org_study_id>
    <nct_id>NCT03976960</nct_id>
  </id_info>
  <brief_title>Clinical and Biological Database in Colon Cancer and Colic Tumors</brief_title>
  <acronym>BCBCOLON</acronym>
  <official_title>Prospective, Multicenter, Clinical and Biological Database Set-up in Colon Cancer and Colic Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Developement of a clinical and biological database in colon cancer and colic tumors in order
      to better understand tumor invasion and metastatic scattering processes. The investigators
      hope that a better understanding of tumoral invasion process will lead to the discovery of
      new biomarkers and new drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As the second leading cause of cancer-related death in France, colorectal cancer is a major
      public health problem. Each year, 37 000 cases are newly diagnosed in France and 17 000
      patients die of the disease.

      Colorectal cancer is due to molecular and genetic damages involved in all tumorigenesis
      steps, transition from healthy tissue to adenoma and finally to invasive carcinoma stage. The
      investigators hope that a to better understand tumor invasion and metastatic scattering
      processes will allow therapeutic innovation and the emergence of new biomarkers.

      However, the study of early tumorigenesis phases as well as advanced stages of the disease is
      currently limited due to a lack of tissue samples.

      In this context, the Montpellier Cancer Institute (ICM) decided to initiate a biological
      collection dedicated to the tissular and blood samples of patients with colorectal cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2018</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of clinical risk factors for colorectal cancer</measure>
    <time_frame>Until the study completion : 6 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of biological risk factors for colorectal cancer</measure>
    <time_frame>Until the study completion : 6 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Cancer Colon</condition>
  <arm_group>
    <arm_group_label>Biological collection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For all the patients include in the study :
samples of blood samples collected before or after surgery but also samples in paraffin-embedded tissue sections.
In parallel to this biological collection, standardized clinical data will be entered into a database</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological collection</intervention_name>
    <description>The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.</description>
    <arm_group_label>Biological collection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient undergoing colon cancer surgery (stage I, II, III and IV)

          2. Patient operated for liver or lung or peritoneal carcinomatosis metastases originating
             from colon cancer

          3. Patient operated for pre-neoplastic lesion (adenomatous polyp /villous adenoma polyp),

          4. Patient with familial polyposis eligible for colectomy

          5. Age &gt; 18 years

          6. Signed informed consent

        Exclusion Criteria:

          1. Patient not affiliated to Social Protection system

          2. Patient unable to understand or comply with study instructions or requirements for
             psychological, family, social or geographical reasons

          3. Patient under guardianship

          4. Minor patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ERIC ASSENAT, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Institut régional du cancer de Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Pierre BLEUSE, M.D</last_name>
    <phone>4 67 61 31 02</phone>
    <phone_ext>+ 33</phone_ext>
    <email>DRCI-icm105@icm.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Assénat, MD</last_name>
      <phone>467330137</phone>
      <phone_ext>+33</phone_ext>
      <email>e-assenat@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Régional du cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ERIC ASSENAT, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>July 5, 2019</last_update_submitted>
  <last_update_submitted_qc>July 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>colon</keyword>
  <keyword>tumor</keyword>
  <keyword>colic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Colic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

